ArticlePloS one2025
Synergistic anticancer effects of ABT-199 and Vorinostat encapsulated in PLGA nanoparticles: Formulation, characterization, and antiproliferative effects against colorectal cancer cells.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigallocatechin gallate enhances panobinostat-induced cytotoxicity through HDAC modulation in colorectal cancer cells.Molecular biology reports · 2026Article
- Epigenetic regulation of the β-catenin pathway in cadmium-induced colorectal cancer progression and chemoresistance.Frontiers in cell and developmental biology · 2026Review
- Exploring the Impact of Nanotherapeutics on Histone H3 and H4 Acetylation Enrichment in Cancer Epigenome: A Systematic Scoping Synthesis.Epigenomes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of ABT-199, a BCL-2 inhibitor, and Vorinostat, a histone deacetylase inhibitor, holds great potential in colorectal cancer therapy due to their synergistic effects. However, their poor solubility and bioavailability present challenges for effective treatment. This study aimed to co-encapsulate these drugs in poly(lactic-co-glycolic acid) nanoparticles to enhance stability, control drug release, and preserve their synergistic anti-proliferative effects in colorectal cancer cells. This study initially focused on evaluating the anti-proliferative activity of free ABT-199 and Vorinostat in HT-29 and HCT116 colorectal cancer cells. The drugs demonstrated potent cytotoxic effects, with Vorinostat exhibiting IC50 values of 1.32 µM in HT-29 cells and 2.04 µM in HCT116 cells, while ABT-199 displayed IC50 values of 4.04 µM and 5.49 µM, respectively. To investigate the interaction between ABT-199 and Vorinostat, the combination index was calculated using the Chou-Talalay method. The analysis revealed strong synergism between the drugs in both cell lines, with CI values consistently below 1 across all tested molar ratios. The most pronounced synergy was observed at a 1:1 molar ratio, which exhibited the lowest CI values. Building on these results, ABT-199-loaded nanoparticles (ABT-NPs), Vorinostat-loaded nanoparticles (VOR-NPs), and dual-loaded nanoparticles (DLNPs) were formulated using the nanoprecipitation method. ABT-NPs and VOR-NPs had sizes of 210.6 ± 6.2 nm and 202.5 ± 5.6 nm, with encapsulation efficiencies of 73.2 ± 4.81% and 86.4 ± 5.5%, respectively. The DLNPs, which co-encapsulated both drugs at a 1:2 molar ratio, exhibited a size of 210 ± 7.3 nm and maintained good stability. Cytotoxicity studies revealed that both ABT-NPs and VOR-NPs retained comparable anti-proliferative effects to the free drugs, with IC50 values close to those of their unencapsulated counterparts. Furthermore, DLNPs enhanced the anti-proliferative effect, significantly increased the apoptotic cells as measured by flow cytometry which was coincided with an increasing caspase-3 activity in both HT-29 and HCT116 cells, indicating an enhanced apoptotic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.